



Step Therapy Criteria
2018 MSOFLPLUS
Last Updated: 10/06/2017

ATYPICAL ANTIPSYCHOTIC THERAPY - UHCMR

Products Affected

- Fanapt
- Fanapt Titration Pack
- Vraylar

Details

Criteria	Step 1: One of the following oral, single-ingredient, generic atypical antipsychotics: olanzapine, quetiapine, risperidone, ziprasidone. Step 2: Fanapt, Vraylar
-----------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------

CNS STIMULANT THERAPY - UHCMR

Products Affected

- Atomoxetine

Details

Criteria	Step 1: Any one of the following formulary generic products: methylphenidate or a long acting methylphenidate. Step 2: atomoxetine
-----------------	------------------------------------------------------------------------------------------------------------------------------------

FILGRASTIM NON-PREFERRED THERAPY - UHCMR

Products Affected

- Granix
- Neupogen

Details

Criteria	Step 1: Zarxio. Step 2: Neupogen or Granix
----------	--------------------------------------------

LEUKOTRIENE MODIFIER ASTHMA THERAPY - UHCMR

Products Affected

- Zileuton Er
- Zflo
- Zflo Cr

Details

Criteria	Step 1: Generic montelukast. Step 2: Zflo CR or Zflo or zileuton ER
-----------------	---------------------------------------------------------------------

RENAGEL THERAPY - UHCMR

Products Affected

- Renagel TABS

Details

Criteria	Step 1: Renvela. Step 2: Renagel
-----------------	----------------------------------

RIVASTIGMINE PATCH THERAPY - UHCMR

Products Affected

- Rivastigmine Transdermal System

Details

Criteria	Step 1: Formulary generic, oral rivastigmine capsule. Step 2: Rivastigmine transdermal systems
-----------------	------------------------------------------------------------------------------------------------

SNRI THERAPY - UHCMR

Products Affected

- Fetzima
- Fetzima Titration Pack

Details

Criteria	Step 1: Generic venlafaxine extended release capsules. Step 2: Fetzima
----------	------------------------------------------------------------------------

TOPICAL IMMUNOMODULATOR THERAPY - UHCMR

Products Affected

- Elidel
- Tacrolimus OINT

Details

Criteria	Step 1: Any two of the following formulary topical agents: desonide ointment, hydrocortisone 2.5% cream or ointment, aug betamethasone 0.05%, fluocinonide 0.05%. Step 2: Elidel or tacrolimus topical
-----------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

UCERIS ORAL THERAPY - UHCMR

Products Affected

- Uceris TB24

Details

Criteria	Step 1: Either Apriso or Lialda, AND generic sulfasalazine. Step 2: Uceris
-----------------	----------------------------------------------------------------------------

ULORIC THERAPY - UHCMR

Products Affected

- Uloric

Details

Criteria	Step 1: Oral, generic allopurinol. Step 2: Uloric
-----------------	---------------------------------------------------

Plans are insured through UnitedHealthcare Insurance Company or one of its affiliated companies, a Medicare Advantage organization with a Medicare contract and a Medicare-approved Part D sponsor. Enrollment in the plan depends on the plan's contract renewal with Medicare.

[<OVEX3386716_000>]

Formulary ID# 00018047MP

Y0066_130404_093413 CMS Approved